Previous Close | 67.88 |
Open | 68.48 |
Bid | 67.00 x 800 |
Ask | 99.00 x 900 |
Day's Range | 64.35 - 69.85 |
52 Week Range | 52.33 - 126.00 |
Volume | |
Avg. Volume | 190,798 |
Market Cap | 1.141B |
Beta (5Y Monthly) | 1.09 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -14.65 |
Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 161.67 |
CONSHOHOCKEN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), announced today its management team will participate in two upcoming investor conferences: H.C. Wainwright Global Life Sciences Conference Fireside chat at 7:00 AM ET on Tuesday, May 24, 2022. UBS Global Healthcare Conference Fireside chat at 8:30 AM ET on Tuesday, May 24, 2022. The pres
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
MAESTRO-NAFLD-1 late-breaker and three other Madrigal abstracts accepted for oral presentation at the EASL International Liver Congress™Data from the Phase 3 MAESTRO-NAFLD-1 study continue to reinforce the safety and efficacy profiles of resmetiromMadrigal remains on track to disclose topline data from MAESTRO-NASH in the fourth quarter and anticipates filing for accelerated approval under Subpart H next yearPlanned MAESTRO-NASH Outcomes trial, a non-invasive Phase 3 study designed to accelerate